Are there generic versions of Delstrigo?
Delstrigo is a modern fixed-dose combination medicine for HIV-1 treatment manufactured by Merck. Each tablet contains three active substances: doravirine, lamivudine (3TC) and tenofovir disoproxil fumarate (TDF).
The medicine is taken once daily and may be used either as an initial antiretroviral regimen or as a switch option for patients with stable virologic suppression. Any decision to start, stop or change HIV therapy must be made together with a qualified physician.
Are there official generics of Delstrigo?
At present, there are no FDA-approved generic versions of Delstrigo. In public FDA data, Delstrigo is listed as a branded Merck product containing doravirine/lamivudine/tenofovir disoproxil fumarate, and no fully equivalent approved ANDA product for this fixed-dose combination is shown.
The timing of future generic availability depends on patents, exclusivity, the market in question and any possible licensing agreements. Public patent information for Delstrigo and doravirine points to timelines extending into the second half of the 2030s, so early availability of a full generic equivalent on regulated markets is unlikely.
Why are there no generics?
The main reason is doravirine. Lamivudine and tenofovir DF have been available from many generic manufacturers for years, but doravirine is a newer component and remains patent-protected. Because of this, generic manufacturers cannot freely launch a complete Delstrigo copy in most markets.
Can Delstrigo be recreated with separate medicines?
In theory, the Delstrigo regimen can be reproduced with separate products: doravirine 100 mg, lamivudine 300 mg and tenofovir DF 300 mg. In practice, access to doravirine outside the original medicines is limited, and the overall cost may be close to the branded Delstrigo regimen.
Patients should not assemble or change an HIV regimen on their own. HIV treatment decisions require medical assessment of viral load, CD4 count, treatment history, drug resistance, kidney function, comorbidities and possible drug interactions.
What alternatives are available?
If the main reason for searching for a generic is cost, clinicians may consider other modern HIV regimens for which quality generics are already available. Combinations based on dolutegravir, tenofovir and lamivudine are often discussed, but they are not direct substitutes for Delstrigo and are not suitable for every patient.
The choice of an alternative regimen depends on previous treatment, laboratory results, tolerability and individual medical risks. This article is for informational purposes only and does not replace consultation with an HIV specialist.
Summary
Full official generic versions of Delstrigo are not currently available on the regulated US market. The key barrier is doravirine patent protection. Patients who specifically need the DOR/3TC/TDF regimen usually use branded Delstrigo or discuss other acceptable treatment options with their physician.
